EWTX · ISSUER CIK 1710072
Edgewise Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 6 Edgewise Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $1.9M of sales on SEC Form 4.
↗6 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 1 of 5 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$1.9MInsider selling
−$1.9MNet open-market
Oct 2, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 202616:47 | Oct 1, 2026 | EWTX | Director | A · Grant | — | +308 | 25,141 | +1% | — | ||
| Aug 14, 202616:54 | Aug 13, 2026from Aug 12, 2026 | EWTX | CMO | S · Sell10b5-1 | $43.71 | −9,441 | 8,625 | -52% | −$413K | ||
| Aug 14, 202616:54 | Aug 12, 2026 | EWTX | CMO | M · Exercise10b5-1 | — | +12,812 | 18,066 | +244% | — | ||
| Aug 14, 202616:53 | Aug 12, 2026 | EWTX | Chief Scientific Officer, Director | S · Sell | $43.73 | −5,901 | 31,466 | -16% | −$258K | ||
| Aug 14, 202616:53 | Aug 12, 2026 | EWTX | Chief Scientific Officer, Director | M · Exercise | — | +12,812 | 37,367 | +52% | — | ||
| Aug 14, 202616:53 | Aug 12, 2026 | EWTX | General Counsel | S · Sell | $43.82 | −5,016 | 17,697 | -22% | −$220K | ||
| Aug 14, 202616:53 | Aug 12, 2026 | EWTX | General Counsel | M · Exercise | — | +12,499 | 22,713 | +122% | — | ||
| Aug 14, 202616:53 | Aug 12, 2026 | EWTX | Chief Business Officer | S · Sell | $43.81 | −5,100 | 31,826 | -14% | −$223K | ||
| Aug 14, 202616:53 | Aug 12, 2026 | EWTX | Chief Business Officer | M · Exercise | — | +13,281 | 36,926 | +56% | — | ||
| Aug 14, 202616:52 | Aug 12, 2026 | EWTX | President and CEO, Director | S · Sell | $43.68 | −17,971 | 52,488 | -26% | −$785K | ||
| Aug 14, 202616:52 | Aug 12, 2026 | EWTX | President and CEO, Director | M · Exercise | — | +39,844 | 70,459 | +130% | — |